Liz Jones Hollis

Articles by Liz Jones Hollis

RecipharmCobra oral TB vax produces good immune response

Study results published in the journal Vaccine show that the orally delivered ORT-VAC DNA vaccine produced higher immune responses in mice than the injected DNA vaccine, according to RecipharmCobra

WHO's Chan sees anti-vaccine sentiment as "worrisome trend"

In opening the World Health Organization's executive board meeting this week, the head of the body cited anti-vaccine sentiments as a worrisome trend that may be very difficult to change. Noting that

Fiocruz granted royalty-bearing license from iBio

IBio, which focuses on the development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases, has granted a commercial, royalty-bearing

British PM: We will learn from the current flu crisis

British Prime Minister David Cameron has warned that there could be "significant outbreaks" of the flu in coming years, emphasizing the importance of looking into the vaccine ordering process. His

Parts of the U.K. sees flu vax shortages

The BBC is reporting there are shortages of the flu vaccine in some areas, forcing doctors to turn away patients seeking the vaccination. And while the Department of Health has admitted to "local

Vax for cocaine addiction could be on horizon

There may soon be hope for cocaine addicts. A team of researchers has produced a lasting cocaine immunity in mice by giving them a vaccine that combines bits of the common cold virus with a particle

Bavarian Nordic gets good news on Prostvac

Danish biotech Bavarian Nordic saw its stock shoot up after the FDA approved a Phase III trial design for Prostvac, the company's prostate cancer vaccine. The company's stock rose as much as 6.5

Immunovaccine to focus on ovarian cancer

Halifax, Nova Scotia-based Immunovaccine will focus the Phase I/II clinical development plan for DPX-Survivac on ovarian cancer. The decision is based on positive input from leaders in cancer

Medicare panel backs Provenge

A Medicare advisory committee backed Dendreon's prostate cancer vaccine Provenge yesterday, thus increasing the chances federal insurance program will pay for the drug. The treatment costs $93,000 a

UC Irvine team: Alzheimer's vax shows promise

Research presented this week at the Society for Neuroscience meeting showed one vaccine candidate appears both safe and effective in an animal model. A UC Irvine team tested a vaccine developed